Nishanth Thalambedu

Assistant Professor

University of Arkansas for Medical Sciences

faculty

Internal Medicine, College of Medicine

7 h-index 65 pubs 218 cited

Research Areas

Multiple Myeloma Research and Treatments CAR-T cell therapy research Cancer Treatment and Pharmacology Cardiac Valve Diseases and Treatments Meta-analysis and systematic reviews Orthopedic Surgery and Rehabilitation Pharmacological Effects and Toxicity Studies Mechanical Circulatory Support Devices

Links

Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Nishanth Thalambedu's research focuses on clinical outcomes and treatment strategies across various medical conditions. He has investigated the effectiveness of CAR-T cell therapy for relapsed refractory multiple myeloma and the clinical outcomes of patients undergoing TAVI and SAVR in both cancer and non-cancer populations. His work also includes a meta-analysis comparing valve-in-valve TAVR and redo-SAVR for degenerated bioprosthetic aortic valves. Additionally, Thalambedu has studied the role of vertebral augmentation procedures in managing multiple myeloma and explored corneal toxicity associated with belantamab mafodotin. His research also extends to the feasibility of outpatient stem cell transplantation in multiple myeloma, identifying risk factors for hospital admission. Thalambedu has published extensively, with a h-index of 7 and over 200 citations.

Metrics

h-index: 7
Publications: 65
Citations: 218

Selected Publications

Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026) DOI
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025) DOI
Editorial: Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology (2025) DOI
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025) DOI
Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions (2025) DOI
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025) DOI
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA) (2025) DOI
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025) DOI
Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case (2024) DOI
Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024) DOI
HL-697 Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024) DOI
Abstract B009: Exploring the putative Kras-p53 mutational interface for vulnerability (2024) DOI
Demographics and survival outcomes of stage IV male breast cancer: A retrospective analysis of SEER database. (2024) DOI
CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients (2024) DOI
The Role of Vertebral Augmentation Procedures in the Management of Multiple Myeloma (2024) DOI